Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study

Overview

Journal Endocrinol Diabetes Metab

Specialty Endocrinology

Date 2025 Feb 14

PMID 39949069

Authors

Ahmed Y Azzam

Muhammed Amir Essibayi

Nathan Farkas

Mohammed A Azab

Mahmoud M Morsy

Osman Elamin

Adam Elswedy

Ahmed Saad Al Zomia

Hammam A Alotaibi

Ahmed Alamoud

Oday Atallah

Hana J Abukhadijah

Adam A Dmytriw

Amanda Baker

Deepak Khatri

Neil Haranhalli

David J Altschul

Affiliations

Soon will be listed here.

Abstract

Introduction: Idiopathic intracranial hypertension (IIH) is a neurological disorder characterised by elevated intracranial pressure (ICP), predominantly affecting obese women of reproductive age. While GLP-1 receptor agonists have shown promise in IIH management, the potential of dual GIP/GLP-1 receptor activation through tirzepatide remains unexplored. This study aimed to evaluate tirzepatide's efficacy as an adjunctive therapy in IIH management.

Methods: We conducted a retrospective cohort analysis using the TriNetX Global Health Research Network, analysing data through November 2024. Through propensity score matching, we compared 193 tirzepatide-exposed IIH patients with 193 controls receiving standard care. Primary outcomes included papilledema severity, visual function, headache frequency, and treatment resistance, monitored at multiple follow-up timepoints.

Results: Our analysis revealed significant improvements across all measured outcomes in the tirzepatide group. At 24 months, we observed a 68% reduction in papilledema risk (RR 0.320, 95% CI 0.189-0.542, p < 0.001), a 73.9% reduction in visual disturbance and blindness risk (RR 0.261, 95% CI 0.143-0.477, p < 0.001), and a 19.7% reduction in headache risk (RR 0.803, 95% CI 0.668-0.966, p = 0.019). The tirzepatide group demonstrated significant body-mass index reductions, reaching -1.147 kg/m (95% CI [-1.415, -0.879], p < 0.001) at 24 months compared to controls.

Conclusions: Our results demonstrate that tirzepatide, when used as an adjunctive therapy, provides significant therapeutic benefits in IIH management, particularly in improving papilledema and visual outcomes. Our findings suggest that dual GIP/GLP-1 receptor activation may offer advantages over traditional single-receptor therapies, potentially through enhanced metabolic regulation and direct effects on ICP dynamics.

References

Fargen K, Coffman S, Torosian T, Brinjikji W, Nye B, Hui F . "Idiopathic" intracranial hypertension: An update from neurointerventional research for clinicians. Cephalalgia. 2023; 43(4):3331024231161323. DOI: 10.1177/03331024231161323. View

Dubin R, Heymsfield S, Ravussin E, Greenway F . Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps. Diabetes Obes Metab. 2024; 26(12):5503-5518. DOI: 10.1111/dom.15913. View

Azzam A, Mortezaei A, Morsy M, Essibayi M, Ghozy S, Elamin O . Venous sinus stenting for idiopathic intracranial hypertension: An updated Meta-analysis. J Neurol Sci. 2024; 459:122948. DOI: 10.1016/j.jns.2024.122948. View

Khatkar P, Hubbard J, Hill L, Sinclair A, Mollan S . Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials. Expert Opin Investig Drugs. 2023; 32(12):1123-1131. DOI: 10.1080/13543784.2023.2288073. View

Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M . Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain. 2023; 24(1):89. PMC: 10353241. DOI: 10.1186/s10194-023-01631-z. View

Zhou C, Zhou Y, Liu L, Jiang H, Wei H, Zhou C . Progress and recognition of idiopathic intracranial hypertension: A narrative review. CNS Neurosci Ther. 2024; 30(8):e14895. PMC: 11298205. DOI: 10.1111/cns.14895. View

Azzam A, Nassar M, Al Zomia A, Elswedy A, Morsy M, Mohamed A . Safety and Efficacy of Metformin for Idiopathic Intracranial Hypertension. A U.S-Based Real-World Data Retrospective Multicenter Cohort Study. ASIDE Intern Med. 2025; 1(1):12-19. PMC: 11734492. DOI: 10.71079/2024001001. View

Mitchell J, Lyons H, Walker J, Yiangou A, Grech O, Alimajstorovic Z . The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023; 146(5):1821-1830. PMC: 10151178. DOI: 10.1093/brain/awad003. View

Westgate C, Markey K, Mitchell J, Yiangou A, Singhal R, Stewart P . Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension. Eur J Endocrinol. 2022; 187(2):323-333. PMC: 9346265. DOI: 10.1530/EJE-22-0108. View

10.

Mollan S, Tahrani A, Sinclair A . The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension: Body Weight. Neurol Clin Pract. 2021; 11(4):e504-e507. PMC: 8382420. DOI: 10.1212/CPJ.0000000000001063. View

11.

Fareed A, Ghanem L, Vaid R, Iftikhar Z, Ur Rehman A, Sarwar A . Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide. Endocr Pract. 2024; 31(1):102-113. DOI: 10.1016/j.eprac.2024.09.004. View

12.

Palchuk M, London J, Perez-Rey D, Drebert Z, Winer-Jones J, Thompson C . A global federated real-world data and analytics platform for research. JAMIA Open. 2023; 6(2):ooad035. PMC: 10182857. DOI: 10.1093/jamiaopen/ooad035. View

13.

Korsbaek J, Jensen R, Beier D, Wibroe E, Hagen S, Molander L . Metabolic Dysfunction in New-Onset Idiopathic Intracranial Hypertension: Identification of Novel Biomarkers. Ann Neurol. 2024; 96(3):595-607. DOI: 10.1002/ana.27010. View

14.

Halloum W, Dughem Y, Beier D, Pellesi L . Glucagon-like peptide-1 (GLP-1) receptor agonists for headache and pain disorders: a systematic review. J Headache Pain. 2024; 25(1):112. PMC: 11241973. DOI: 10.1186/s10194-024-01821-3. View

15.

Westgate C, Botfield H, Alimajstorovic Z, Yiangou A, Walsh M, Smith G . Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight. 2021; 6(10). PMC: 8262372. DOI: 10.1172/jci.insight.145346. View

16.

Potter O, Menon V, Mollan S . Risk factors and disease associations in people living with idiopathic intracranial hypertension. Expert Rev Neurother. 2024; 24(7):681-689. DOI: 10.1080/14737175.2024.2359420. View

17.

Kassubek R, Weinstock D, Behler A, Muller H, Dupuis L, Kassubek J . Morphological alterations of the hypothalamus in idiopathic intracranial hypertension. Ther Adv Chronic Dis. 2022; 13:20406223221141354. PMC: 9720803. DOI: 10.1177/20406223221141354. View

18.

Colman B, Boonstra F, Nguyen M, Raviskanthan S, Sumithran P, White O . Understanding the pathophysiology of idiopathic intracranial hypertension (IIH): a review of recent developments. J Neurol Neurosurg Psychiatry. 2023; 95(4):375-383. DOI: 10.1136/jnnp-2023-332222. View

19.

Markey K, Mollan S, Jensen R, Sinclair A . Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2015; 15(1):78-91. DOI: 10.1016/S1474-4422(15)00298-7. View

20.

Samanci B, Samanci Y, Tuzun E, Altiokka-Uzun G, Ekizoglu E, Icoz S . Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension. Cephalalgia. 2016; 37(6):525-531. DOI: 10.1177/0333102416650705. View